Global Oral Anti-Diabetic Drugs Market - 2023-2030

Global Oral Anti-Diabetic Drugs Market - 2023-2030

The global Oral Anti-Diabetic Drugs Market reached US$ 44.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 80.8 billion by 2030. The global oral anti-diabetic drugs market is expected to exhibit a CAGR of 8.0% during the forecast period (2023-2030).

Based on a number of variables, such as the patient's unique characteristics, medical history, and treatment objectives, the specific oral anti-diabetic medications used in the treatment of type 2 diabetes vary in patients. For instance, SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin function by preventing the kidneys' reabsorption of glucose, which causes an increase in urine glucose excretion and a decrease in blood sugar levels.

Market Dynamics

The Increasing Research Activities Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.

For instance, in December 2022, Pfizer notified Sosei Group Corporation, a global leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, that the candidate medicine PF-07081532 from Pfizer has been dosed to the first subject in Phase 2 clinical trial. When this goal is reached, Sosei Heptares will get a payment of $10 million USD.

Next-generation oral small molecule GLP-1 receptor agonist PF-07081532 is being developed as a once-daily treatment for Type 2 diabetes and obesity. In multi-target research cooperation where Pfizer has access to Sosei Heptare's unique StaR (stabilized receptor) technology, Pfizer scientists made the discovery of PF-07081532. The Pfizer-conducted Phase 1 clinical trial for PF-07081532 was successful.

The Growing Awareness And Government Initiatives Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.

The largest diabetes awareness campaign in the world, World Diabetes Day reaches over one billion individuals in more than 160 countries. The primary goal of honoring this day is to raise awareness of diabetes and encourage people to take action to address this major global health concern. Access to Diabetes Care is the focus of World Diabetes Day 2021–23. ""Education to Protect Tomorrow"" is the focus of the World Diabetes Day 2021–23 campaign's second year.

The emphasis of the campaign 2022 was on the requirement for improved accessibility to high-quality diabetes education for medical professionals and diabetic patients. Activities will emphasize the importance of improving health professionals' and diabetes patients' access to high-quality diabetes education.

Personalized Medicines Provide Oral Anti-Diabetic Drugs Market Growth Opportunities

Rapid developments in data science and technology have the potential to increase the accuracy of therapeutic and preventative interventions and make it possible to recommend the correct treatment to the right patient at the right time. A ""one size fits all"" strategy is ineffective for treating type 2 diabetes since it is a complex, heterogeneous, and polygenic palette of metabolic diseases.

The efficient analysis of thousands of genes, proteins, and metabolites is now possible due to technological advancements in genetics, genomics, proteomics, and metabolomics. This presents new opportunities for identifying genetic factors and gene products that are linked to various subtypes of diseases, such as diabetes mellitus.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the oral anti-diabetic drugs market. Patient behavior has changed as a result of COVID-19, including a decrease in visits to medical facilities and an increase in reliance on remote healthcare services. The demand for these medications may have been impacted because some diabetics may have had trouble getting access to oral anti-diabetes medications or sticking to their treatment plans.

As of 2023, the COVID-19 situation is recovering and all healthcare facilities are accessible for patients and can give proper treatment leading o increasing demand for oral anti-diabetic drugs worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the oral anti-diabetic drugs market is complex and multifaceted. Population displacement may occur as a result of the conflict because people may be compelled to evacuate their homes or seek safety elsewhere. Access to healthcare services, especially oral diabetes medications, is difficult for displaced people, which could interrupt the management of their diabetes. Both Russia and Ukraine have had negative economic impacts from the conflict. The pricing and availability of oral anti-diabetes medications for both individuals and healthcare systems are impacted by economic instability, currency fluctuations, and inflationary pressures.

Segment Analysis

The global oral anti-diabetic drugs market is segmented based on drug class, dosage type, distribution channel, and region.

The Dopamine -D2 Receptor Agonist Segment Is Expected To Hold A Position In The Market Over The Forecast Period.

The Dopamine -D2 receptor agonist segment accounted for 26.5% market share in the Oral Anti-Diabetic Drugs market in 2022. The research provides insights into the exact mechanism by which bromocriptine mesylate enhances glycemic control. However, it has been demonstrated that bromocriptine mesylate treatment in the morning improves glycemic control in T2D patients without raising plasma insulin concentrations.

This might be connected to the diurnal peak in central dopaminergic tone brought on by morning administration of the quick-release bromocriptine formulation in the brain regions that control peripheral fuel metabolism (including glucose, lipid metabolism, and protein metabolism).

Geographical Analysis

Increasing Collaborations And Partnerships Among The Key Players And Increasing Product Launches Dominate the Asia Pacific Region.

Asia Pacific is expected to dominate the oral anti-diabetic drugs market, accounting for around 24.4% of this market. For instance, in January 2022, earlier exclusively available as injections anti-diabetic medication has now been made available orally by Novo Nordisk India. The company reported that the new medication can help adults with type-2 diabetes better regulate their weight and blood sugar levels.

A naturally occurring hormone called glucagon-like peptide 1 is crucial in preserving the proper level of blood glucose. The only problem with peptide and protein-based biological treatments is that they must be administered intravenously, despite the fact that they are often quite successful.

Competitive Landscape

The major global players in the market include Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, and Bristol-Myers Squibb among others.

Why Purchase the Report?
• To visualize the global oral anti-diabetic drugs market segmentation based on the drug class, dosage type, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of oral anti-diabetic drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global oral anti-diabetic drugs market report would provide approximately 62 tables, 61 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies